NeoGenomics heads into its July 28 earnings report with options markets flashing the most defensive signal in months, even as short sellers show little conviction.
The sharpest move in the data is in options positioning. The put/call ratio jumped to 0.054 — more than two standard deviations above its 20-day mean of 0.017, making it the highest defensive reading since June. For a stock where the PCR has spent most of the past month below 0.011, that shift is notable. It lands against a week of softness in the stock, which has given back nearly 5% to close at $13.89, erasing a portion of the 21% rally built over the prior month. The hedging impulse appears tied to that recent run-up rather than fundamental deterioration — the borrow market tells a notably calmer story.
Short interest does not support the thesis that bears are pressing hard here. At 8.9% of the free float, short positions have grown roughly 28% over the past month — tracking the stock's rally, not fighting it. Yet borrow availability is loose, running at around 303% of outstanding short interest, well within normal territory and near the top of its year-range. Cost to borrow is a modest 0.57%, up about 53% from a month ago but still among the lowest readings for any meaningfully shorted stock. With days to cover at six and no squeeze pressure evident, the elevated short float looks more like a structural overhang than an active attack.
The analyst community has swung meaningfully bullish in recent months. Benchmark raised its price target from $11 to $16 on July 24 — the day before earnings — while maintaining its Buy rating. That follows an April upgrade from Leerink Partners, which moved to Outperform with a $25 target. The consensus mean now sits at $16.78, implying roughly 21% upside from current levels. Bulls point to the company's improving margin trajectory — adjusted gross margin expanding 150 basis points to 46.8%, with NGS testing revenue up 18% in the most recent quarter — and strong forward EPS momentum that ranks in the 95th percentile. Bears flag the softer non-clinical revenue line, which came in at $18.3 million against a $20.9 million estimate, plus ongoing exposure to reimbursement risk and competitive pressure.
Past prints have leaned positive. The last two reported quarters both produced single-day gains of roughly 3-4%, with the May event extending to a 14% rally over the following five days. The earnings report on Monday will test whether the margin expansion story can offset renewed concern about the non-clinical revenue trajectory — and whether the stock's recent run has already priced in the good news.
See the live data behind this article on ORTEX.
Open NEO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
